Global Serum Clot Activator Tubes Market Set to Reach USD 2.5 billion by 2034, Fuelled by Diagnostic Testing Boom
Serum Clot Activator Tubes Market Outlook 2025-2034
Luton, Bedfordshire, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- The global serum clot activator tubes market is projected to reach a valuation of approximately USD 1.5 billion in 2024. Looking ahead, the market is expected to grow significantly, reaching around USD 2.5 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of approximately 5.2% over the forecast period from 2025 to 2034.
Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/53935/global-serum-clot-activator-tubes-market#request-a-sample
At present, the market is witnessing steady growth, primarily driven by the rising demand for diagnostic testing and continual advancements in laboratory technologies. Key market trends include the increasing adoption of point-of-care testing and a heightened focus on improving the efficiency and accuracy of blood collection procedures.
However, the market faces certain headwinds. Challenges such as stringent regulatory compliance and concerns regarding biohazard waste management could potentially hinder growth.
Despite these constraints, the market presents notable opportunities. Innovations in materials and tube design aimed at enhancing performance, along with the growing shift toward home-based testing solutions, are expected to open new avenues for product development. As the healthcare landscape evolves, these factors will play a pivotal role in shaping the future of the serum clot activator tubes market, fostering an environment ripe for growth and innovation throughout the next decade.
Key Market Drivers:
Diagnostic testing surge: 61% increase in demand for rapid blood analysis
Lab automation adoption: 64% of modern laboratories now use automation-compatible tubes
Preventive healthcare growth: 58% rise in routine screenings driving tube utilization
Chronic disease prevalence: 65% of routine blood tests now require serum separation
Technology and Material Trends:
Plastic dominance: PET tubes now command 69% market share, replacing traditional glass
Enhanced activators: Silica-based formulations improving clotting speed by 42%
Smart integration: 44% of new tubes feature barcode/RFID tracking capabilities
Eco-friendly solutions: 32% of manufacturers now offering sustainable variants
Regional Market Landscape:
North America leads with 34% global share (U.S. accounts for 71% of regional demand)
Europe follows at 28%, driven by stringent quality standards
Asia-Pacific growing fastest (47% demand increase in emerging markets)
Middle East & Africa showing promise with expanding diagnostic infrastructure
Clinical Applications:
Hospitals & clinics: 64% of total usage (78% of labs prefer clot activator tubes)
Chronic disease monitoring: Used in 71% of diabetes/cardiovascular tests
Point-of-care testing: 58% growth in decentralized healthcare settings
Industry Challenges:
Regulatory hurdles: 47% of product launches face approval delays
Cost pressures: 41% of labs report budget constraints
Supply chain disruptions: 33% impact on product availability
Training gaps: 35% of facilities need better staff education
Innovation Spotlight:
BD's 100% recyclable PET tubes reducing lab plastic waste
Greiner Bio-One's micro-sample tubes for paediatric applications
Terumo's 35% production expansion in Southeast Asia
Sarstedt's RFID-enabled tubes enhancing sample traceability
Browse full Report - https://exactitudeconsultancy.com/reports/53935/global-serum-clot-activator-tubes-market
Market Dynamics
One of the primary drivers of the serum clot activator tubes market is the surging demand for diagnostic testing. The growing prevalence of chronic illnesses and the frequent emergence of infectious diseases have underscored the need for widespread and reliable diagnostic procedures. Notably, the COVID-19 pandemic significantly amplified global testing volumes, reinforcing the importance of efficient blood collection systems, including serum clot activator tubes.
Another critical factor fuelling market expansion is the advancement of laboratory technologies. Innovations in blood collection and processing—such as automated collection systems and integrated platforms that streamline sample handling—are improving both the accuracy and speed of diagnostic workflows. These technological upgrades are prompting laboratories to adopt more sophisticated serum tube solutions.
Regulatory developments also shape the market landscape. Stricter compliance standards and heightened focus on patient safety are compelling manufacturers to prioritize product quality and consistency. As a result, there is growing demand for serum clot activator tubes engineered to meet rigorous and evolving regulatory benchmarks.
Lastly, economic trends—particularly increased healthcare spending and infrastructural investments in healthcare systems across various regions—are creating favourable conditions for market growth. With greater budget allocations towards diagnostics and healthcare services, the demand for essential tools like serum clot activator tubes is expected to rise steadily.
Buy Now : https://exactitudeconsultancy.com/purchase/?currency=USD&type=single_user_license&report_id=53935
Future Outlook: The market is poised for continued growth as:
Automation adoption spreads to 63% of global labs
Preventive screening programs expand worldwide
Emerging markets upgrade diagnostic capabilities
Smart technologies (barcoding, RFID) become standard
Sustainable materials gain wider acceptance
Key Players Strategizing for Growth:
BD (Becton, Dickinson and Company)
Terumo Corporation
Greiner Bio-One International GmbH
Sarstedt AG & Co. KG
Roche Diagnostics
Sekisui Medical Co., Ltd.
Qiagen N.V.
Medtronic plc
Hemostatics, Inc.
Cardinal Health
Eurotrol B.V.
Labcorp
Hologic, Inc.
PerkinElmer, Inc.
SUNNY Medical Co., Ltd.
These industry leaders are focusing on:
Automation-compatible designs
Enhanced clotting formulations
Sustainable materials
Emerging market expansion
Smart tracking technologies
Growth Opportunities & Emerging Trends
Opportunities
The serum clot activator tubes market presents numerous growth opportunities fueled by innovation and changing consumer dynamics. One of the key areas of opportunity lies in the development of advanced materials and innovative tube designs. These improvements can enhance clot activation efficiency, optimize sample integrity, and simplify waste disposal—addressing some of the current challenges in clinical workflows.
Another promising avenue is the growing shift toward home-based diagnostic solutions. As consumers increasingly prioritize convenience and accessibility, demand is rising for blood collection devices that are safe and easy to use outside traditional clinical environments. Serum clot activator tubes tailored for home-testing kits offer manufacturers a chance to tap into this expanding segment, easing the burden on healthcare facilities while empowering patients.
Emerging digital health technologies and telemedicine are further transforming the diagnostics landscape. The integration of smart technologies—such as connected blood collection systems and user-friendly digital interfaces—can significantly enhance the patient experience. These innovations not only support remote diagnostics but also align with the broader move toward personalized, patient-centric healthcare.
Additionally, shifts in consumer expectations, including the demand for faster diagnostic results and real-time health monitoring, are reshaping product requirements. The rise of point-of-care testing necessitates the development of specialized serum clot activator tubes that meet the needs of rapid and decentralized testing environments.
Finally, investment in telehealth and remote patient monitoring is creating fertile ground for market expansion. Manufacturers that embrace these trends and align their product strategies with modern healthcare delivery models stand to gain a competitive edge and capture substantial market share in the coming years.
This report is also available in the following languages : Japanese (ロール式昇降装置市場), Korean (롤 리프팅 장비 시장), Chinese (卷筒起重设备市场), French (Marché des équipements de levage de rouleaux), German (Markt für Rollenhebegeräte), and Italian (Mercato delle attrezzature per il sollevamento di rotoli), etc.
Get a Sample PDF Brochure:https://exactitudeconsultancy.com/reports/53935/global-serum-clot-activator-tubes-market#request-a-sample
More Related Reports:
No Additive Collection Tubes Market
The global market for non-additive collection tubes is valued at approximately $2.3 billion in 2024, with projections indicating a compound annual growth rate (CAGR) of 6.5%, pushing the market value to around $4.1 billion by 2034.
https://exactitudeconsultancy.com/reports/53936/global-no-additive-collection-tubes-market
Blood Glucose Collection Tubes Market
The global blood glucose collection tubes market is valued at approximately $1.2 billion. This market is expected to grow significantly, reaching an estimated $2.5 billion by 2034, driven by the increasing prevalence of diabetes and the demand for reliable and efficient blood sampling solutions. The forecasted Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is projected at 7.5%, reflecting a robust growth trajectory propelled by advancements in healthcare technology and continuous innovations in product designs.
https://exactitudeconsultancy.com/reports/53937/global-blood-glucose-collection-tubes-market
Wearable Smart Patch Market
The global wearable smart patch market is valued at approximately $3 billion, with an anticipated growth trajectory fueled by advancements in healthcare technology and increasing consumer demand for remote monitoring solutions. The projected market value is expected to reach around $10 billion by 2034, indicating significant expansion over the next decade.
https://exactitudeconsultancy.com/reports/53938/global-wearable-smart-patch-market
Patch Thermometer Market
The global patch thermometer market is valued at approximately $320 million in 2024 and is projected to reach around $520 million by 2034. This reflects a robust Compound Annual Growth Rate (CAGR) of 5.1% over the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53939/global-patch-thermometer-market
Fully Automated Clinical Chemistry Analyzer Market
The global market for fully automated clinical chemistry analyzers was valued at approximately $9.3 billion in 2024. Projections indicate substantial growth, with a forecasted market value of around $14.2 billion by 2034, reflecting increasing integration of automation in laboratory settings. The projected compound annual growth rate (CAGR) for the period from 2025 to 2034 is estimated at 5.6%.
https://exactitudeconsultancy.com/reports/53943/global-fully-automated-clinical-chemistry-analyzer-market
Mobile MRI Scanner Market
The global mobile MRI scanner market is projected to reach a valuation of approximately $2.5 billion in 2024, with a robust forecast to grow to around $4.5 billion by 2034. This represents a compound annual growth rate (CAGR) of about 6.3% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53944/global-mobile-mri-scanner-market
Medical Gas Monitoring System Market
The global medical gas monitoring system market is valued at approximately $550 million in 2024. This market is projected to reach around $1.2 billion by 2034, driven by an increasing emphasis on patient safety and regulatory compliance in healthcare settings. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is expected to be approximately 8.5%.
https://exactitudeconsultancy.com/reports/53951/global-medical-gas-monitoring-system-market
Portable ATP Hygiene Monitoring System Market
The global market for portable ATP hygiene monitoring systems is valued at approximately $250 million. The market is expected to grow significantly over the forecast period, with a projected value of about $500 million by 2034. This growth trajectory reflects a Compound Annual Growth Rate (CAGR) of approximately 7.4%, driven by increasing awareness of hygiene standards in various sectors, including food and beverage, pharmaceuticals, and healthcare.
https://exactitudeconsultancy.com/reports/53955/global-portable-atp-hygiene-monitoring-system-market
Medical Ceiling Supply Unit Market
The global medical ceiling supply unit market is valued at approximately $6.5 billion, reflecting an increasing demand driven by advancements in healthcare infrastructure and the rising emphasis on infection control in medical facilities. The market is anticipated to grow significantly over the forecast period from 2025 to 2034, with a projected market value reaching approximately $10.2 billion by 2034. This translates to a Compound Annual Growth Rate (CAGR) of around 5.1%.
https://exactitudeconsultancy.com/reports/53956/global-medical-ceiling-supply-unit-market
Medical Supply Pendants Market
The global medical supply pendants market is valued at approximately $580 million in 2024, with expectations to reach around $970 million by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of approximately 5.2% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53958/global-medical-supply-pendants-market
Automatic Visual Vial Inspection Machine Market
The global market for Automatic Visual Vial Inspection Machines was valued at approximately $580 million in 2024 and is projected to reach around $1.1 billion by 2034. This indicates a remarkable growth trajectory, with a Compound Annual Growth Rate (CAGR) of approximately 6.7% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53978/global-automatic-visual-vial-inspection-machine-market
Patient Isolation Room Market
The global patient isolation room market is valued at approximately $2.5 billion in 2024, with projections estimating it will reach around $5 billion by 2034. This growth represents a compound annual growth rate (CAGR) of approximately 7.4% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53987/global-patient-isolation-room-market
Portable Negative Air Machine Market
The global portable negative air machine market is valued at approximately $450 million in 2024 and is projected to reach around $750 million by 2034, reflecting increasing awareness of indoor air quality and air purification technologies. The market is expected to experience a Compound Annual Growth Rate (CAGR) of about 5.2% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53990/global-portable-negative-air-machine-market
Medical Tent Market
The global medical tent market is valued at approximately $1.5 billion in 2024, with projections indicating a market value of around $2.8 billion by 2034. This growth trajectory reflects a compound annual growth rate (CAGR) of approximately 6.8% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53991/global-medical-tent-market
Dental Examination Gloves Market
The global dental examination gloves market is valued at approximately $1.1 billion in 2024, driven by a rising demand for infection control and enhanced patient safety protocols. The market is projected to reach about $1.7 billion by 2034, reflecting increasing awareness among dental professionals regarding hygiene standards and the use of advanced materials for glove manufacturing.
https://exactitudeconsultancy.com/reports/53993/global-dental-examination-gloves-market
Modular Isolation Room Market
The global modular isolation room market is projected to reach a value of approximately $4.5 billion in 2024, driven by an increasing demand for efficient healthcare solutions amidst rising infection control challenges. The market is expected to experience significant growth, with a projected value of around $9.7 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8.3% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53997/global-modular-isolation-room-market
Negative Pressure Isolation Room Market
The global market for Negative Pressure Isolation Rooms (NPIRs) is valued at approximately $1.2 billion in 2024, with projections estimating a growth to around $2.1 billion by 2034. This trajectory reflects a robust Compound Annual Growth Rate (CAGR) of approximately 6.0% between 2025 and 2034.
https://exactitudeconsultancy.com/reports/53998/global-negative-pressure-isolation-room-market
Pharmaceutical Cleanroom Air Shower Market
The global pharmaceutical cleanroom air shower market is valued at approximately $250 million in 2024 and is expected to reach around $400 million by 2034, indicating a robust growth trajectory. This growth corresponds to a Compound Annual Growth Rate (CAGR) of approximately 5.0% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/54009/global-pharmaceutical-cleanroom-air-shower-market
In-ear Hearing Aids Market
The global in-ear hearing aids market is valued at approximately $6.5 billion in 2024, driven by an increasing prevalence of hearing loss and an aging population. As healthcare systems enhance accessibility and awareness of auditory technologies, the market is poised for significant growth. Between 2025 and 2034, the market is projected to reach around $10 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of 5.4%.
https://exactitudeconsultancy.com/reports/54013/global-in-ear-hearing-aids-market
Automatic Tablet Hardness Tester Market
The global market for automatic tablet hardness testers is valued at approximately $180 million in 2024, with a projected growth to around $290 million by 2034. This anticipated increase reflects a significant Compound Annual Growth Rate (CAGR) of about 4.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/54015/global-automatic-tablet-hardness-tester-market
CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@exactitudeconsultancy.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNN
an hour ago
- CNN
How Trump's pick for surgeon general uses her big online following to make money
Trump appointments Social media Donald Trump MediaFacebookTweetLink Follow President Donald Trump's pick to be the next U.S. surgeon general has repeatedly said the nation's medical, health and food systems are corrupted by special interests and people out to make a profit at the expense of Americans' health. Yet as Dr. Casey Means has criticized scientists, medical schools and regulators for taking money from the food and pharmaceutical industries, she has promoted dozens of health and wellness products — including specialty basil seed supplements, a blood testing service and a prepared meal delivery service — in ways that put money in her own pocket. A review by The Associated Press found Means, who has carved out a niche in the wellness industry, set up deals with an array of businesses. In her newsletter, on her social media accounts, on her website, in her book and during podcast appearances, the entrepreneur and influencer has at times failed to disclose that she could profit or benefit in other ways from sales of products she recommends. In some cases, she promoted companies in which she was an investor or adviser without consistently disclosing the connection, the AP found. Means, 37, has said she recommends products that she has personally vetted and uses herself. She is far from the only online creator who doesn't always follow federal transparency rules that require influencers to disclose when they have a 'material connection' to a product they promote. Still, legal and ethics experts said those business entanglements raise concerns about conflicting interests for an aspiring surgeon general, a role responsible for giving Americans the best scientific information on how to improve their health. 'I fear that she will be cultivating her next employers and her next sponsors or business partners while in office,' said Jeff Hauser, executive director of the Revolving Door Project, a progressive ethics watchdog monitoring executive branch appointees. The nomination, which comes amid a whirlwind of Trump administration actions to dismantle the government's public integrity guardrails, also has raised questions about whether Levels, a company Means co-founded that sells subscriptions for devices that continuously monitor users' glucose levels, could benefit from this administration's health guidance and policy. Though scientists debate whether continuous glucose monitors are beneficial for people without diabetes, U.S. Health Secretary Robert F. Kennedy Jr. has promoted their use as a precursor to making certain weight-loss drugs available to patients. The aspiring presidential appointee has built her own brand in part by criticizing doctors, scientists and government officials for being 'bought off' or 'corrupt' because of ties to industry. Means' use of affiliate marketing and other methods of making money from her recommendations for supplements, medical tests and other health and dietary products raise questions about the extent to which she is influenced by a different set of special interests: those of the wellness industry. Means earned her medical degree from Stanford University, but she dropped out of her residency program in Oregon in 2018, and her license to practice is inactive. She has grown her public profile in part with a compelling origin story that seeks to explain why she left her residency and conventional medicine. 'During my training as a surgeon, I saw how broken and exploitative the healthcare system is and left to focus on how to keep people out of the operating room,' she wrote on her website. Means turned to alternative approaches to address what she has described as widespread metabolic dysfunction driven largely by poor nutrition and an overabundance of ultra-processed foods. She co-founded Levels, a nutrition, sleep and exercise-tracking app that can also give users insights from blood tests and continuous glucose monitors. The company charges $199 per year for an app subscription and an additional $184 per month for glucose monitors. Means has argued that the medical system is incentivized not to look at the root causes of illness but instead to maintain profits by keeping patients sick and coming back for more prescription drugs and procedures. 'At the highest level of our medical institutions, there are conflicts of interest and corruption that are actually making the science that we're getting not as accurate and not as clean as we'd want it,' she said on Megyn Kelly's podcast last year. But even as Means decries the influence of money on science and medicine, she has made her own deals with business interests. During the same Megyn Kelly podcast, Means mentioned a frozen prepared food brand, Daily Harvest. She promoted that brand in a book she published last year. What she didn't mention in either instance: Means had a business relationship with Daily Harvest. Influencer marketing has expanded beyond the beauty, fashion and travel sectors to 'encompass more and more of our lives,' said Emily Hund, author of 'The Influencer Industry: The Quest for Authenticity on Social Media.' With more than 825,000 followers on Instagram and a newsletter that she has said reached 200,000 subscribers, Means has a direct line into the social media feeds and inboxes of an audience interested in health, nutrition and wellness. Affiliate marketing, brand partnerships and similar business arrangements are growing more popular as social media becomes increasingly lucrative for influencers, especially among younger generations. Companies might provide a payment, free or discounted products or other benefits to the influencer in exchange for a post or a mention. But most consumers still don't realize that a personality recommending a product might make money if people click through and buy, said University of Minnesota professor Christopher Terry. 'A lot of people watch those influencers, and they take what those influencers say as gospel,' said Terry, who teaches media advertising and internet law. Even his own students don't understand that influencers might stand to benefit from sales of the products they endorse, he added. Many companies, including Amazon, have affiliate marketing programs in which people with substantial social media followings can sign up to receive a percentage of sales or some other benefit when someone clicks through and buys a product using a special individualized link or code shared by the influencer. Means has used such links to promote various products sold on Amazon. Among them are books, including the one she co-wrote, 'Good Energy'; a walking pad; soap; body oil; hair products; cardamom-flavored dental floss; organic jojoba oil; a razor set; reusable kitchen products; sunglasses; a sleep mask; a silk pillowcase; fitness and sleep trackers; protein powder and supplements. She also has shared links to products sold by other companies that included 'affiliate' or 'partner' coding, indicating she has a business relationship with the companies. The products include an AI-powered sleep system and Daily Harvest, for which she curated a 'metabolic health collection.' On a 'My Faves' page that was taken down from her website shortly after Trump picked her, Means wrote that some links 'are affiliate links and I make a small percentage if you buy something after clicking them.' It's not clear how much money Means has earned from her affiliate marketing, partnerships and other agreements. Daily Harvest did not return messages seeking comment, and Means said she could not comment on the record during the confirmation process. Means has raised concerns that scientists, regulators and doctors are swayed by the influence of industry, oftentimes pointing to public disclosures of their connections. In January, she told the Kristin Cavallari podcast 'Let's Be Honest' that 'relationships are influential.' 'There's huge money, huge money going to fund scientists from industry,' Means said. 'We know that when industry funds papers, it does skew outcomes.' In November, on a podcast run by a beauty products brand, Primally Pure, she said it was 'insanity' to have people connected to the processed food industry involved in writing food guidelines, adding, 'We need unbiased people writing our guidelines that aren't getting their mortgage paid by a food company.' On the same podcast, she acknowledged supplement companies sponsor her newsletter, adding, 'I do understand how it's messy.' Influencers who endorse or promote products in exchange for payment or something else of value are required by the Federal Trade Commission to make a clear and conspicuous disclosure of any business, family or personal relationship. While Means did provide disclosures about newsletter sponsors, the AP found in other cases Means did not always tell her audience when she had a connection to the companies she promoted. For example, a 'Clean Personal & Home Care Product Recommendations' guide she links to from her website contains two dozen affiliate or partner links and no disclosure that she could profit from any sales. Means has said she invested in Function Health, which provides subscription-based lab testing for $500 annually. Of the more than a dozen online posts the AP found in which Means mentioned Function Health, more than half did not disclose she had any affiliation with the company. Means also listed the supplement company Zen Basil as a company for which she was an 'Investor and/or Advisor.' The AP found posts on Instagram, X and on Facebook where Means promoted its products without disclosing the relationship. Though the 'About' page on her website discloses an affiliation with both companies, that's not enough, experts said. She is required to disclose any material connection she has to a company anytime she promotes it. Representatives for Function Health did not return messages seeking comment through their website and executives' LinkedIn profiles. Zen Basil's founder, Shakira Niazi, did not answer questions about Means' business relationship with the company or her disclosures of it. She said the two had known each other for about four years and called Means' advice 'transformational,' saying her teachings reversed Niazi's prediabetes and other ailments. 'I am proud to sponsor her newsletter through my company,' Niazi said in an email. While the disclosure requirements are rarely enforced by the FTC, Means should have been informing her readers of any connections regardless of whether she was violating any laws, said Olivier Sylvain, a Fordham Law School professor who was previously a senior adviser to the FTC chair. 'What you want in a surgeon general, presumably, is someone who you trust to talk about tobacco, about social media, about caffeinated alcoholic beverages, things that present problems in public health,' Sylvain said, adding, 'Should there be any doubt about claims you make about products?' Means isn't the first surgeon general nominee whose financial entanglements have raised eyebrows. Jerome Adams, who served as surgeon general from 2017 to 2021, filed federal disclosure forms that showed he invested in several health technology, insurance and pharmaceutical companies before taking the job — among them Pfizer, Mylan and UnitedHealth Group. He also invested in the food and drink giant Nestle. He divested those stocks when he was confirmed for the role and pledged that he and his immediate family would not acquire financial interest in certain industries regulated by the Food and Drug Administration. Vivek Murthy, who served as surgeon general twice, under Presidents Barack Obama and Joe Biden, made more than $2 million in COVID-19-related speaking and consulting fees from Carnival, Netflix, Estee Lauder and Airbnb between holding those positions. He pledged to recuse himself from matters involving those parties for a period of time. Means has not yet gone through a Senate confirmation hearing and has not yet announced the ethical commitments she will make for the role. Hund said that as influencer marketing becomes more common, it is raising more ethical questions, such as what past influencers who enter government should do to avoid the appearance of a conflict. Other administration officials, including Homeland Security Secretary Kristi Noem and Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz, have also promoted companies on social media without disclosing their financial ties. 'This is like a learning moment in the evolution of our democracy,' Hund said. 'Is this a runaway train that we just have to get on and ride, or is this something that we want to go differently?'


TechCrunch
an hour ago
- TechCrunch
Genetics testing startup Nucleus Genomics criticized for its embryo product: ‘Makes me so nauseous'
Nucleus Genomics, a genetic testing startup founded by 25-year-old Kian Sadeghi, initially launched in 2021 with the goal of calculating a patient's risk for specific diseases. But it's been courting controversy for years with products that claim to tell people how their genetics correlate to a host of complex issues, including their IQ. On Wednesday, it ratcheted up the controversy to an ear-splitting level when it announced a new product called Nucleus Embryo with a tweet that said: 'Every parent wants to give their children more than they had. For the first time in human history, Nucleus adds a new tool to that commitment.' Every parent wants to give their children more than they had. For the first time in human history, Nucleus adds a new tool to that commitment. Welcome to Nucleus — Nucleus Genomics (@nucleusgenomics) June 4, 2025 Nucleus says it can test IVF embryos not just for well-known specific genes that have a high chance of illnesses like breast cancer, but also for appearance — sex, height, hair color, eye color — as well as IQ and complex health attributes like anxiety and ADHD. The launch video includes a screen shot of a comparison menu. The idea is to help parents choose which embryos to pick and which ones to, perhaps, discard. Nucleus Genomics embryos features screen Image Credits:Nucleus Genomics (opens in a new window) Genetic testing of embryos isn't unheard of. IVF physicians can test for genes that can cause conditions like Down syndrome, or when parents know they are of high risk for a particular genetic disorder, like cystic fibrosis. Techcrunch event Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Boston, MA | REGISTER NOW But that's not exactly what Nucleus is doing. It is using controversial 'polygenic scores' to determine 'complex genetic outcomes, like intelligence and anxiety,' a spokesperson says. According to the National Human Genome Research Institute, polygenic scores only calculate the probabilities of a certain complex illness occurring, mainly within populations. 'A polygenic risk score can only explain the relative risk for a disease,' the NHGR says. This is not the same as discovering a specific gene, such as for example the BRCA1 gene mutation, which gives a person a 60-80% 'absolute risk of breast cancer,' the NHGR says. There's a reason doctors don't typically use such tests for individuals. 'Polygenic risk scores are not yet routinely used by health professionals because there are no guidelines for practice and researchers are still improving how these scores are generated,' according to the NHGR. Nucleus defends that its method can be used to determine an individual's risk. The spokesperson pointed us to a 2018 paper where the authors said they had developed validated methods for five common diseases: coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer. That paper was advocating screenings to help individuals make lifestyle or therapeutic decisions, similar to Nucleus's initial concept. Wednesday's tweet was promising parents that Nucleus can help them create designer babies. It has now been viewed more than 4 million times and has hundreds of comments, many of them either expressing disbelief that this works as promised, or horror at the idea. One VC chimed into the discussion saying, 'I was going to type something like Noah get the boat but honestly the reality of this just makes me so nauseous.' I was going to type something like Noah get the boat but honestly the reality of this just makes me so nauseous — Max Niederhofer ❤️🔥 (@maxniederhofer) June 5, 2025 Nucleus has experienced this kind of controversy before, as TechCrunch previously reported, when it its $14 million series A earlier this year. The startup is backed by Founders Fund, Alexis Ohanian's 776, and angels including Adrian Aoun (CEO at Forward Health), Brent Saunders (former CEO at Allergan), and Matteo Franceschetti (CEO at Eight Sleep). Last year, Sadeghi launched Nucleus IQ, which is supposed to tell users how much their genetics influence intelligence. The product was blasted as 'bad science and big business' by some critics. Sadeghi published a lengthy defense of his company's methodology. Even so, telling adults that they are genetically smart is one thing. Telling IVF parents that they can choose the appearance and other complex attributes for their children is, many would argue, something else. Nucleus is not currently conducting such tests via IVF lab partners itself, The Wall Street Journal reports. It's partnering with Genomic Prediction, which works with IVF clinics. A Genomic executive told the WSJ that many parents request intelligence tests, and it doesn't provide that. Parents can voluntarily upload genetic data information to Nucleas if they want to pursue it. Or, as Sadeghi said in the launch video aimed at would-be parents: 'Not that long ago IVF-1 sparked fear and the stigma of test tube babies,' he said. 'What was once controversial is now an everyday practice. The same is true with genetic optimization. The technology is now here and it's here to stay.'


CNN
an hour ago
- CNN
How Trump's pick for surgeon general uses her big online following to make money
Trump appointments Social media Donald Trump MediaFacebookTweetLink Follow President Donald Trump's pick to be the next U.S. surgeon general has repeatedly said the nation's medical, health and food systems are corrupted by special interests and people out to make a profit at the expense of Americans' health. Yet as Dr. Casey Means has criticized scientists, medical schools and regulators for taking money from the food and pharmaceutical industries, she has promoted dozens of health and wellness products — including specialty basil seed supplements, a blood testing service and a prepared meal delivery service — in ways that put money in her own pocket. A review by The Associated Press found Means, who has carved out a niche in the wellness industry, set up deals with an array of businesses. In her newsletter, on her social media accounts, on her website, in her book and during podcast appearances, the entrepreneur and influencer has at times failed to disclose that she could profit or benefit in other ways from sales of products she recommends. In some cases, she promoted companies in which she was an investor or adviser without consistently disclosing the connection, the AP found. Means, 37, has said she recommends products that she has personally vetted and uses herself. She is far from the only online creator who doesn't always follow federal transparency rules that require influencers to disclose when they have a 'material connection' to a product they promote. Still, legal and ethics experts said those business entanglements raise concerns about conflicting interests for an aspiring surgeon general, a role responsible for giving Americans the best scientific information on how to improve their health. 'I fear that she will be cultivating her next employers and her next sponsors or business partners while in office,' said Jeff Hauser, executive director of the Revolving Door Project, a progressive ethics watchdog monitoring executive branch appointees. The nomination, which comes amid a whirlwind of Trump administration actions to dismantle the government's public integrity guardrails, also has raised questions about whether Levels, a company Means co-founded that sells subscriptions for devices that continuously monitor users' glucose levels, could benefit from this administration's health guidance and policy. Though scientists debate whether continuous glucose monitors are beneficial for people without diabetes, U.S. Health Secretary Robert F. Kennedy Jr. has promoted their use as a precursor to making certain weight-loss drugs available to patients. The aspiring presidential appointee has built her own brand in part by criticizing doctors, scientists and government officials for being 'bought off' or 'corrupt' because of ties to industry. Means' use of affiliate marketing and other methods of making money from her recommendations for supplements, medical tests and other health and dietary products raise questions about the extent to which she is influenced by a different set of special interests: those of the wellness industry. Means earned her medical degree from Stanford University, but she dropped out of her residency program in Oregon in 2018, and her license to practice is inactive. She has grown her public profile in part with a compelling origin story that seeks to explain why she left her residency and conventional medicine. 'During my training as a surgeon, I saw how broken and exploitative the healthcare system is and left to focus on how to keep people out of the operating room,' she wrote on her website. Means turned to alternative approaches to address what she has described as widespread metabolic dysfunction driven largely by poor nutrition and an overabundance of ultra-processed foods. She co-founded Levels, a nutrition, sleep and exercise-tracking app that can also give users insights from blood tests and continuous glucose monitors. The company charges $199 per year for an app subscription and an additional $184 per month for glucose monitors. Means has argued that the medical system is incentivized not to look at the root causes of illness but instead to maintain profits by keeping patients sick and coming back for more prescription drugs and procedures. 'At the highest level of our medical institutions, there are conflicts of interest and corruption that are actually making the science that we're getting not as accurate and not as clean as we'd want it,' she said on Megyn Kelly's podcast last year. But even as Means decries the influence of money on science and medicine, she has made her own deals with business interests. During the same Megyn Kelly podcast, Means mentioned a frozen prepared food brand, Daily Harvest. She promoted that brand in a book she published last year. What she didn't mention in either instance: Means had a business relationship with Daily Harvest. Influencer marketing has expanded beyond the beauty, fashion and travel sectors to 'encompass more and more of our lives,' said Emily Hund, author of 'The Influencer Industry: The Quest for Authenticity on Social Media.' With more than 825,000 followers on Instagram and a newsletter that she has said reached 200,000 subscribers, Means has a direct line into the social media feeds and inboxes of an audience interested in health, nutrition and wellness. Affiliate marketing, brand partnerships and similar business arrangements are growing more popular as social media becomes increasingly lucrative for influencers, especially among younger generations. Companies might provide a payment, free or discounted products or other benefits to the influencer in exchange for a post or a mention. But most consumers still don't realize that a personality recommending a product might make money if people click through and buy, said University of Minnesota professor Christopher Terry. 'A lot of people watch those influencers, and they take what those influencers say as gospel,' said Terry, who teaches media advertising and internet law. Even his own students don't understand that influencers might stand to benefit from sales of the products they endorse, he added. Many companies, including Amazon, have affiliate marketing programs in which people with substantial social media followings can sign up to receive a percentage of sales or some other benefit when someone clicks through and buys a product using a special individualized link or code shared by the influencer. Means has used such links to promote various products sold on Amazon. Among them are books, including the one she co-wrote, 'Good Energy'; a walking pad; soap; body oil; hair products; cardamom-flavored dental floss; organic jojoba oil; a razor set; reusable kitchen products; sunglasses; a sleep mask; a silk pillowcase; fitness and sleep trackers; protein powder and supplements. She also has shared links to products sold by other companies that included 'affiliate' or 'partner' coding, indicating she has a business relationship with the companies. The products include an AI-powered sleep system and Daily Harvest, for which she curated a 'metabolic health collection.' On a 'My Faves' page that was taken down from her website shortly after Trump picked her, Means wrote that some links 'are affiliate links and I make a small percentage if you buy something after clicking them.' It's not clear how much money Means has earned from her affiliate marketing, partnerships and other agreements. Daily Harvest did not return messages seeking comment, and Means said she could not comment on the record during the confirmation process. Means has raised concerns that scientists, regulators and doctors are swayed by the influence of industry, oftentimes pointing to public disclosures of their connections. In January, she told the Kristin Cavallari podcast 'Let's Be Honest' that 'relationships are influential.' 'There's huge money, huge money going to fund scientists from industry,' Means said. 'We know that when industry funds papers, it does skew outcomes.' In November, on a podcast run by a beauty products brand, Primally Pure, she said it was 'insanity' to have people connected to the processed food industry involved in writing food guidelines, adding, 'We need unbiased people writing our guidelines that aren't getting their mortgage paid by a food company.' On the same podcast, she acknowledged supplement companies sponsor her newsletter, adding, 'I do understand how it's messy.' Influencers who endorse or promote products in exchange for payment or something else of value are required by the Federal Trade Commission to make a clear and conspicuous disclosure of any business, family or personal relationship. While Means did provide disclosures about newsletter sponsors, the AP found in other cases Means did not always tell her audience when she had a connection to the companies she promoted. For example, a 'Clean Personal & Home Care Product Recommendations' guide she links to from her website contains two dozen affiliate or partner links and no disclosure that she could profit from any sales. Means has said she invested in Function Health, which provides subscription-based lab testing for $500 annually. Of the more than a dozen online posts the AP found in which Means mentioned Function Health, more than half did not disclose she had any affiliation with the company. Means also listed the supplement company Zen Basil as a company for which she was an 'Investor and/or Advisor.' The AP found posts on Instagram, X and on Facebook where Means promoted its products without disclosing the relationship. Though the 'About' page on her website discloses an affiliation with both companies, that's not enough, experts said. She is required to disclose any material connection she has to a company anytime she promotes it. Representatives for Function Health did not return messages seeking comment through their website and executives' LinkedIn profiles. Zen Basil's founder, Shakira Niazi, did not answer questions about Means' business relationship with the company or her disclosures of it. She said the two had known each other for about four years and called Means' advice 'transformational,' saying her teachings reversed Niazi's prediabetes and other ailments. 'I am proud to sponsor her newsletter through my company,' Niazi said in an email. While the disclosure requirements are rarely enforced by the FTC, Means should have been informing her readers of any connections regardless of whether she was violating any laws, said Olivier Sylvain, a Fordham Law School professor who was previously a senior adviser to the FTC chair. 'What you want in a surgeon general, presumably, is someone who you trust to talk about tobacco, about social media, about caffeinated alcoholic beverages, things that present problems in public health,' Sylvain said, adding, 'Should there be any doubt about claims you make about products?' Means isn't the first surgeon general nominee whose financial entanglements have raised eyebrows. Jerome Adams, who served as surgeon general from 2017 to 2021, filed federal disclosure forms that showed he invested in several health technology, insurance and pharmaceutical companies before taking the job — among them Pfizer, Mylan and UnitedHealth Group. He also invested in the food and drink giant Nestle. He divested those stocks when he was confirmed for the role and pledged that he and his immediate family would not acquire financial interest in certain industries regulated by the Food and Drug Administration. Vivek Murthy, who served as surgeon general twice, under Presidents Barack Obama and Joe Biden, made more than $2 million in COVID-19-related speaking and consulting fees from Carnival, Netflix, Estee Lauder and Airbnb between holding those positions. He pledged to recuse himself from matters involving those parties for a period of time. Means has not yet gone through a Senate confirmation hearing and has not yet announced the ethical commitments she will make for the role. Hund said that as influencer marketing becomes more common, it is raising more ethical questions, such as what past influencers who enter government should do to avoid the appearance of a conflict. Other administration officials, including Homeland Security Secretary Kristi Noem and Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz, have also promoted companies on social media without disclosing their financial ties. 'This is like a learning moment in the evolution of our democracy,' Hund said. 'Is this a runaway train that we just have to get on and ride, or is this something that we want to go differently?'